FDA Approved Products

190 products with lifecycle intelligence, competitive pressure scores, and patent timelines.

Type:AllNDABLAANDA
Lifecycle:GrowthPeakLOE ApproachingPost-LOELaunchPre-Launch
Sort:Approval DateNameCompetitive Pressure↓
Active:Lifecycle: GrowthClear all
HYDROMORPHONE HYDROCHLORIDE
hydromorphone hydrochloride
Growth
Hikma
INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS · SOLUTION
pain severe enough to require an opioid analgesicfor which alternate treatments are inadequate
2023
NDA
45/100
ABACAVIR SULFATE AND LAMIVUDINE
abacavir sulfate; lamivudine
Growth
ORAL · TABLET, FOR SUSPENSION
HIV-1 infection
2023
NDA
30/100
AXTLE
pemetrexed
Growth
Viatris (2)
INTRAVENOUS · POWDER
non-small cell lung cancerlung cancer
2024
NDA
30/100
BORTEZOMIB
bortezomib
Growth
Medica Corp
INTRAVENOUS, SUBCUTANEOUS · SOLUTION
myelomalymphoma
2024
NDA
30/100
CABAZITAXEL
cabazitaxel
Growth
Teva
INTRAVENOUS · SOLUTION
combination with prednisone for treatment of patients with metastatic castration-resistant prostate cancer previously treated with a docetaxel-containing treatment regimenprostate cancer
2024
NDA
30/100
CARBON DIOXIDE, USP
carbon dioxide
Growth
INHALATION · GAS
2024
NDA
30/100
CARBON DIOXIDE, USP
carbon dioxide
Growth
INHALATION · GAS
2024
NDA
30/100
CEFAZOLIN SODIUM
cefazolin sodium
Growth
R-Pharm US
INTRAVENOUS · POWDER
incidence of certain postoperative infections in patients undergoing surgical procedures which are classifiedpotentially contaminated (e
2023
NDA
30/100
CHEWTADZY
tadalafil
Growth
ORAL · TABLET, CHEWABLE
erectile dysfunction (ED)the signs+2
2024
NDA
30/100
COXANTO
oxaprozin
Growth
ORAL · CAPSULE
rheumatoid arthritisFor relief of the signs and symptoms of osteoarthritis
2023
NDA
30/100
CYCLOPHOSPHAMIDE
cyclophosphamide injection, solution
Growth
Baxter
INTRAVENOUS · SOLUTION
lymphocytic lymphomamixed-cell type lymphoma+5
2023
NDA
30/100
CYCLOPHOSPHAMIDE
cyclophosphamide
Growth
Novartis
INTRAVENOUS · SOLUTION
lymphocytic lymphomamixed-cell type lymphoma+9
2023
NDA
30/100
Carbon Dioxide, USP
carbon dioxide
Growth
INHALATION · GAS
2024
NDA
30/100
Carbon Dioxide, USP
carbon dioxide
Growth
INHALATION · GAS
2025
NDA
30/100
DAPTOMYCIN
daptomycin
Growth
MAIA Biotechnology
INTRAVENOUS · POWDER
pneumonialeft-sided infective endocarditis due to S+13
2024
NDA
30/100
DILTIAZEM HYDROCHLORIDE IN 0.72% SODIUM CHLORIDE
diltiazem hydrochloride
Growth
R-Pharm US
INTRAVENOUS · SOLUTION
atrial flutteratrial fibrillation
2025
NDA
30/100
EPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE
epinephrine
Growth
Baxter
INTRAVENOUS · SOLUTION
2025
NDA
30/100
HEMICLOR
chlorthalidone
Growth
ORAL · TABLET
hypertension in adultsto lower blood pressure+1
2025
NDA
30/100
MEDICAL AIR, USP
medical air
Growth
INHALATION · GAS
2024
NDA
30/100
MEROPENEM
meropenem
Growth
R-Pharm US
INTRAVENOUS · POWDER
bacterial meningitis caused by Haemophilus influenzaeNeisseria meningitidis andpenicillin-susceptible isolates of Streptococcus pneumoniae+1
2023
NDA
30/100
NILOTINIB D-TARTRATE
nilotinib
Growth
Cipla
ORAL · CAPSULE
2025
SMNDA
30/100
PACLITAXEL
paclitaxel
Growth
Teva
INTRAVENOUS · POWDER
breast cancer after failure of combination chemotherapy for metastatic diseaserelapse within 6 months of adjuvant chemotherapy+2
2023
NDA
30/100
PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE
pantoprazole sodium in 0.9% sodium chloride
Growth
Baxter
INTRAVENOUS · SOLUTION
pathological hypersecretory conditions including Zollinger-Ellison (ZE) Syndrome in adults
2024
NDA
30/100
PIVYA
pivmecillinam
Growth
ORAL · TABLET
female patients 18 years of ageolder with uncomplicated urinary tract infections (uUTI) caused by susceptible isolates of Escherichia coli+3
2024
NDA
30/100
Page 1 of 8Next →